Clinical trials: Synucleinopathies
Parkinson Disease
Ophthalmologic Safety Study of Pramipexole Immediate Release (IR) Versus Ropinirole in Early Parkinson's Disease (PD) Patients
To determine if there is any difference in the presence of retinal deterioration in PD patients treated with pramipexole IR versus ropinirole as monitored by comprehensive ophthalmologic assessments from baseline to the end of…
- Trial name
- NCT00144300
- Testing
- Mirapex, Requip
- Where
- 21 sites in United States
- Volunteers
- 246 people
- Sponsor
- Boehringer Ingelheim
Early Parkinson Disease
PROSEEK: A Phase 2 Study In Early Parkinson's Disease Patients Evaluating The Safety And Efficacy Of Abl Tyrosine Kinase Inhibition Using K0706
This study consists of 2 parts. Part 1 of the study is conducted to evaluate the efficacy, safety, and tolerability of two doses of K0706 compared to placebo in subjects with early Parkinson's Disease who are not receiving…
- Trial name
- NCT03655236
- Testing
- K0706
- Where
- 78 sites in United States, Hungary and 4 more
- Volunteers
- 513 people
- Sponsor
- Sun Pharma Advanced Research Company Limited
Parkinson Disease
A Late Phase II Clinical Trial of KDT-3594 in Patients With Parkinson's Disease
This trial is a late phase II, multicenter, randomized, double-blind, placebo-controlled, parallel group trial to evaluate the efficacy, safety, and pharmacokinetics of KDT-3594 administered at escalating doses ranging from 0.25…
- Trial name
- NCT06722729
- Testing
- KDT-3594
- Where
- Japan
- Volunteers
- 178 people
- Sponsor
- Kissei Pharmaceutical Co., Ltd.
Parkinson's Disease Psychosis
A Study of the Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis
This study will evaluate the safety and efficacy of two dose levels of pimavanserin (ACP-103) compared to placebo in patients with Parkinson's disease psychosis.
- Trial name
- NCT00477672
- Testing
- Pimavanserin tartrate (ACP-103)
- Where
- 78 sites in United States, Bulgaria and 5 more
- Volunteers
- 298 people
- Sponsor
- ACADIA Pharmaceuticals Inc.
Parkinson Disease
Treatment of Balance Disorders in Parkinson's Patients Using SpotOn Balance Glasses
An open-label study to evaluate the effect of SpotOn balance glasses in non-demented Parkinson's patients with balance disorders.
- Trial name
- NCT03942172
- Testing
- SpotOn balance glasses
- Where
- Israel
- Volunteers
- 50 people
- Sponsor
- SpotOn Therapeutics Ltd.
Dementia With Lewy Bodies (DLB)
A Clinical Study of Neflamapimod in Patients With Dementia With Lewy Bodies
The purpose of this clinical study is to evaluate the safety and tolerability (side effects) and pharmacokinetics (drug levels in the body) of 80mg neflamapimod given twice daily in patients with dementia with Lewy bodies.
- Trial name
- NCT06815965
- Testing
- neflamapimod
- Where
- 2 sites in France
- Volunteers
- 26 people
- Sponsor
- EIP Pharma Inc
Parkinson Disease, Parkinson's Disease
A Long-Term Follow-up Study of the Severe Parkinson's Disease Patients Administered the IPS101A Gene Therapy Product.
The purpose of this study is to evaluate the long-term safety of IPS101A and to assess the durability of efficacy in subjects who received IPS101A.
- Trial name
- NCT07629115
- Where
- South Korea
- Volunteers
- 6 people
- Sponsor
- Innopeutics Corporation
Parkinson Disease, Early Parkinson's Disease
A Phase 3 Study With P2B001 in Subjects With Early Parkinson's
P2B001 is an investigational drug that comprised of low doses of two drugs, pramipexole and rasagiline, which are both approved drugs and routinely used in standard therapy for Parkinson's disease.
- Trial name
- NCT03329508
- Testing
- P2B001 0.6/0.75 mg, Rasagiline 0.75 mg, Pramipexole 0.6 mg
- Where
- 72 sites in United States, Canada and 2 more
- Volunteers
- 544 people
- Sponsor
- Pharma Two B Ltd.
Parkinson Disease
A Study to Assess the Safety of BMS-984923 Compared to Placebo, in People With Parkinson's
A Phase 1, randomized, double-blind, placebo-controlled study of BMS-984923 administered orally twice daily (BID) for 28 days in participants with Parkinson's disease.
- Trial name
- NCT06309147
- Testing
- BMS-9894923
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Allyx Therapeutics
Parkinson's Disease
Long-term Follow-up of Glutamic Acid Decarboxylase (GAD) Gene Transfer in Parkinson's Disease
The objective of this study is to evaluate the long-term safety of AAV-GAD delivered bilaterally to the subthalamic nuclei (STN) in participants with Parkinson's disease.
- Trial name
- NCT05894343
- Testing
- AAV-GAD
- Where
- 6 sites in United States
- Volunteers
- 13 people
- Sponsor
- MeiraGTx, LLC
Parkinson Disease, Idiopathic Parkinson Disease
Study to Determine Mutations in the Gaucher Gene in Patients With Idiopathic Parkinson's Disease for Phenotype-genotype Correlation
The genotype-phenotype correlation in patients with Parkinson's disease with specific mutations in the glucocerebrosidase gene (Gaucher gene) is known from own clinical experiences as well as from case reports in the literature.
- Trial name
- PadGau (NCT01272687)
- Where
- 15 sites in Germany, Thailand
- Volunteers
- 1,500 people
- Sponsor
- CENTOGENE GmbH Rostock
Parkinson Disease
Observational Small Intestine and Blood Fingerprint (SmIle) Study in Parkinson's Disease
Observational cross-sectional study in PD patients and healthy controls (HC) using an investigational medical device consisting of a passive small intestine microbiome aspiration (SIMBA) system (capsule) that is ingested orally…
- Trial name
- SmIle (NCT06003608)
- Testing
- Fluid biopsy capsule, Levodopa-Carbidopa Immediate Release
- Where
- Canada
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- Nimble Science Ltd.
Idiopathic Parkinson Disease
A Study to Evaluate in Patients With Parkinsonian Type Disorders
A Phase 2 study to evaluate the safety, tolerability and initial efficacy of pramipexole ER, given with aprepitant in patients with parkinsonian type disorders
- Trial name
- NCT03683225
- Testing
- CTC-413
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Chase Therapeutics Corporation
Parkinson Disease
A Two-Part Single and Multiple Ascending Dose Trial of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LBT-3627 in Healthy Participants and in Participants With Parkinson's Disease.
Phase I a/b SAD/MAD study to evaluate safety and tolerability of LBT-3627 in both healthy volunteers and Parkinson's patients.
- Trial name
- NCT06466525
- Testing
- LBT-3627
- Where
- 3 sites in Australia
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Longevity Biotech Australia Pty Ltd (subsidiary)
Parkinson's Disease, Quality of Life
Study of the Application of Magnetic Fields for the Treatment of Parkinson's Disease
The purpose of this study is to see if a device called the Resonator can help to improve aspects of health and quality of life that are relevant to patients with Parkinson's disease.
- Trial name
- NCT00863226
- Testing
- Resonator Device
- Where
- 6 sites in United States
- Volunteers
- 72 people
- Sponsor
- pico-tesla Magnetic Therapies, LLC
Parkinson's Disease
Satisfaction Survey on PINS Stimulator System for Patients With Parkinson's Disease
This study will be done because the investigators would like to evaluate product satisfaction of two PINS products (product A, product B) that are to evaluate the effectiveness of rechargeable and non-rechargeable Deep Brain…
- Trial name
- NCT02251808
- Where
- China
- Volunteers
- 612 people
- Sponsor
- Beijing Pins Medical Co., Ltd
Parkinson Disease, Gait Disorders, Neurologic
Automated Mechanical Peripheral Stimulation to Treat Freezing of Gait in Patients With Parkinson's Disease and STN-DBS
The objective is to investigate whether AMPS (Automated Mechanical Peripheral Stimulation) is effective in reduction of FOG measured via the FOG-AC (Freezing Of Gait Assessment Course) in people with Parkinson Disease and STN-DBS…
- Trial name
- AMBITION (NCT04831879)
- Testing
- GONDOLA AMPS
- Where
- Germany
- Volunteers
- 40 people
- Sponsor
- Gondola Medical Technologies SA
Parkinson's Disease
Rasagiline as Add on to Dopamine Agonists in the Treatment of Parkinson's Disease
To assess the efficacy of rasagiline 1 mg as a first add-on treatment to dopamine agonist therapy in early Parkinson Disease (PD) patients, , not optimally controlled on dopamine agonists as compared to placebo.
- Trial name
- ANDANTE (NCT01049984)
- Testing
- Rasagiline
- Where
- 58 sites in United States
- Volunteers
- 328 people
- Sponsor
- Teva Neuroscience, Inc.
Parkinson Disease
A Study to Evaluate the Pharmacokinetics and Safety of LY03003 in Patients With Advanced-stage PD
This study is to evaluate the pharmacokinetics and safety of LY03003 in patients with advanced-stage PD.
- Trial name
- NCT04630860
- Testing
- LY03003
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Luye Pharma Group Ltd.
Parkinson Disease
Comparative Controlled Study of Analgesic, Antiasthenic and Anti-Anxiety Effects of Xenon in Patients With Parkinson's Disease
This study evaluates the hypothesis that the gas mixture with xenon will have a positive effect on the symptoms in patients with Parkinson's Disease.
- Trial name
- NCT04097080
- Testing
- NBTX-001, Standard of Care
- Where
- 2 sites in Russia
- Volunteers
- 60 people
- Sponsor
- Nobilis Therapeutics Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.